The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...